Expression of tensin 4 in hepatocellular carcinoma and its role in epithelial-mesenchymal transformation

Table 2 Relationship between tensin 4 protein expression and clinicopathological features in hepatocellular carcinoma, n (%)

Clinicopathological feature		n	Negative expression	Positive expression	P value
Sex	Male	54	12 (22.22)	42 (77.78)	0.569
	Female	48	13 (27.08)	35 (72.92)
Age (years)	< 60	67	17 (25.37)	50 (74.63)	0.779
	> 60	35	8 (21.05)	27 (78.95)
Hepatitis B/C surface antigen	Positive	68	19 (27.94)	49 (72.06)	0.255
	Negative	34	6 (17.65)	28 (82.35)
Liver cirrhosis	Yes	79	18 (22.78)	61 (77.22)	0.453
	No	23	7 (30.43)	16 (69.57)
Liver function classification	Child-Pugh A	74	15 (20.27)	59 (79.73)	0.106
	Child-Pugh B	28	10 (35.71)	18 (64.29)
Tumor size, cm	> 5	41	11 (26.83)	30 (73.17)	0.655
	< 5	61	14 (22.95)	47 (77.05)
Tumor number	Single	84	18 (21.43)	66 (78.57)	0.118
	Multiple	18	7 (38.89)	11 (61.11)
AFP level (ng/mL)	> 400	64	13 (20.31)	51 (79.69)	0.201
	< 400	38	12 (31.58)	26 (68.42)
Vascular invasion	Yes	39	5 (12.82)	34 (87.18)	0.031
	No	63	20 (31.75)	43 (68.25)
Cancer embolism	Yes	38	5 (13.16)	33 (86.84)	0.04
	No	64	20 (31.25)	44 (68.75)
Pathological grade	I/II	59	19 (32.20)	40 (67.80)	0.034
	III/IV	43	6 (13.95)	37 (86.05)
TNM staging	I	61	17 (27.87)	44 (72.13)	0.336
	II/III	41	8 (19.51)	33 (80.49)

AFP: Alpha-fetoprotein.